Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Multiparametric nanoelectronic biosensors for therapy response testing

Project description

Protease sensors for disease diagnosis

Proteases, known for their role in breaking down proteins into smaller polypeptides, play a crucial role in various diseases by modulating protein activity and degradation. Dysregulated protease activity has been linked to various conditions. As such, proteases have emerged as valuable biomarkers for disease diagnosis and progression. However, real-time analysis of disease-associated protease activity remains a challenge. The EU-funded MUNASET project aims to develop a graphene-based biosensor platform for detecting multiple proteases in serum using a sensing mechanism that does not require protein-labelling. Researchers will initially validate the system for major depressive disorder but plan to expand its application to other diseases, advancing point-of-care diagnostics.

Objective

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum. We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response. There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD. The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools. This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-CL4-2022-DIGITAL-EMERGING-02

See all projects funded under this call

Coordinator

HOCHSCHULE KAISERSLAUTERN
Net EU contribution
€ 1 357 007,50
Address
SCHOENSTR 11
67659 Kaiserslautern
Germany
Region
Rheinland-Pfalz Rheinhessen-Pfalz Kaiserslautern, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 357 007,50

Participants (5)